Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on September 22, 2017, reporting events occurring on September 22 and September 25, 2017. The Company is an emerging growth company focused on the development and commercialization of Mytesi® (crofelemer), a prescription drug approved by the U.S. FDA.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses on a material definitive agreement rather than periodic financial performance.
Material Changes
On September 22, 2017, Jaguar Health's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., entered into a Termination, Asset Transfer and Transition Agreement with Glenmark Pharmaceuticals Ltd. Key changes include:
- Asset Recovery: Napo regained commercial rights for crofelemer in India and 140 other countries, largely in developing regions, previously licensed to Glenmark.
- Global Control: The Company now controls commercial rights for Mytesi® for all indications, territories, and patient populations globally.
- Regulatory Rights: Napo holds commercial rights to existing regulatory approvals for crofelemer in Brazil, Ecuador, Zimbabwe, and Botswana.
- Manufacturing: Napo agreed to enter into a new manufacturing and supply agreement with Glenmark within 90 days, utilizing Glenmark's facilities in India.
Guidance, Outlook, and Consideration
The filing outlines the financial consideration for the asset transfer:
- Contingent Payment: Napo agreed to pay Glenmark 25% of any payment received from third-party licenses, sublicenses, partnerships, or sales of the Transferred Assets. This payment continues until Glenmark receives a total of $7 million.
- Payment Timing: Payments are due within 45 days after Napo receives funds from third parties.
- Equipment Transfer: Napo agreed to transfer certain dedicated manufacturing equipment located at Glenmark's Ankleshwar facility to Glenmark.
Investor Verification Checklist
- Verify the execution of the new manufacturing and supply agreement with Glenmark within the 90-day window.
- Monitor the status of regulatory approvals in Brazil, Ecuador, Zimbabwe, and Botswana to ensure commercial viability.
- Track potential third-party licensing deals that would trigger the 25% royalty payment to Glenmark up to the $7 million cap.
- Confirm the transfer of dedicated manufacturing equipment from Glenmark's Ankleshwar facility.